Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838742 · ClinicalTrials.gov registry record · Phase 2
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
NCT05838742 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 314 participants.
The verdict
NCT05838742, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
Study Summary
This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279.
Interventions
- DRUG Placebo
- DRUG GSK3858279
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05838742
The ClinicalTrials.gov registry entry for NCT05838742 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05838742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05838742 about?
NCT05838742 is a clinical study titled "A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain". This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279.
What is the current status of trial NCT05838742?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2023-09-13. Estimated completion is 2024-12-03.
What interventions are being tested in trial NCT05838742?
The interventions under investigation include: Placebo (DRUG), GSK3858279 (DRUG).
Who is sponsoring clinical trial NCT05838742?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.